We evaluated the number and characteristics of randomized controlled trials (RCTs) addressing hematopoietic stem cell transplantation (HSCT) for patients with hematological malignancies, comparing the productivity of US and Europe. A MEDLINE search was conducted to identify all published RCTs for the management of adult patients with hematological malignancies from January 1992 to December 2003. Eighty-three of the 306 trials identified included HSCT as one of the treatment arms. The US produced 25, Europe 54, and all other countries four. Four European countries, France, Italy, Germany, and UK (FIGU), produced 32 out of the 54 European studies. Significant differences emerged when focus of the study and accrual numbers were analyzed. Trials comparing HSCT to standard dose therapy represented 34.9% of the 83 trials and 59.4% of FIGU trials, but only 4% of US studies (P ¼ 0.001). US trials accrued a mean of 110.2 patients per study, as compared to 222.6 in FIGU studies (P ¼ 0.006) and 205.3 when all non-US countries are considered (P ¼ 0.01). Our conclusions are that US transplant RCT have focused on issues other than the comparison of HSCT to standard therapies. There is serious paucity of US trials defining the role of HSCT in the management of hematological malignancies.
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Introduction/background
Randomized controlled trials (RCTs) provide the highest level of evidence available when standard therapies are defined and when critical treatment decisions for individual patients are made. 1, 2 RCTs remain the cornerstone of evidence-based medicine. The ability to design, conduct, and report RCTs is essential in establishing the role of new therapies. For more than a decade, a declining American representation in leading clinical research journals and across medical specialties has been reported. 3 For clinical cancer research in particular, concerns over inadequate funding and decreasing numbers of young physicians committed to this field have been discussed in several papers and editorials. [4] [5] [6] These concerns have been extended to RCTs evaluating hematopoietic stem cell transplantation (HSCT). 7 Most studies evaluate trends in clinical research activity by the number of grants or the amount of funds allocated. There are relatively few studies that have evaluated clinical research productivity as measured by the actual number and quality of published RCTs. 8 In this report, we evaluate the number and characteristics of RCTs addressing HSCT for patients with hematological malignancies, including a comparison of patterns of activity in the US and Europe.
Patients and methods
A MEDLINE search, according to published guidelines, was conducted to identify all RCTs for adult patients with hematological malignancies published in the English medical literature. 9 The study period was from January 1992 to December 2003. Multiple key words were used for each subject. The data obtained were crossreferenced with searches of individual journals databases. RCTs published only in abstract form were excluded. Multiple reports of single trials were counted only once.
Data extracted included year of publication, country(s) of origin, number of patients randomized, whether or not HSCT was included as one of the treatment arms, disease(s), and focus of study.
Transplant studies were categorized by the focus of study, according to the question the trial was attempting to answer. These included four groups: (1) comparison of transplant to conventional therapy, (2) comparison of two conditioning regimens, (3) comparison of graft manipulations or use of growth factors, and (4) comparison of approaches for the prevention or treatment of graft-versushost disease (GVHD).
For the purpose of comparing the productivity of US centers to Europe, we pooled the data from four European countries: France, Italy, Germany, and the UK (FIGU). By 1990, the combined population of these four countries was nearly identical to that of the US (250 million). US population grew at a slightly faster rate and by the end of the decade had an excess of approximately 24 million. Further, FIGU enjoys similar social and economic indicators, as well as active research programs, so that comparable research productivity could be expected.
Statistical analysis
The distribution of studies was evaluated across each of the extracted measures and all comparisons were defined a priori. Proportions of studies were compared between defined subgroups using either a Pearson chi-square or Fisher exact test. Study accrual was compared between subgroups using an independent sample t-test for pairwise comparisons and analysis of variance for multigroup comparisons. A multivariate analysis was performed with linear regression on the log mean study accrual. Overall model performance was based on ANOVA and a global F-statistic.
As all comparisons were defined a priori, no modification for multiple testing was employed. Two sided tests were utilized throughout.
Results
We identified a total of 306 RCTs, including 83 transplant trials and 223 nontransplant studies. The US produced a total of 94 RCTs (25 transplant and 69 nontransplant) compared to 110 in FIGU (32 transplant and 78 nontransplant studies). European cooperative groups (studies with the participation of two or more European countries) contributed 33 RCTs and other European countries 42 RCTs. Countries outside of the USA and Europe contributed 26 RCTs.
Publication of RCT activity has remained stable over the period of observation with approximately 20-30 trials published per year, without any significant trends.
Transplant studies, categorized by focus of study included trials of transplantation versus conventional therapy (n ¼ 29, 34%), trials exploring issues of conditioning regimens (n ¼ 11, 13%), trials involving graft manipulations or use of growth factors (n ¼ 31, 37%), and studies on GHVD (n ¼ 12, 14%).
When the focus of study was compared by country of origin (Table 1) , US was the country of origin in 50% of GVHD trials, 45% of graft/growth factor studies, and 36% of conditioning regimen studies, but only 3% of studies comparing transplant to conventional therapy. Only one out of 29 studies in this category was produced in the US. European countries were responsible for 28, with FIGU countries being responsible for nearly 2/3 of these studies.
More than 14 000 patients were randomized in the 83 transplant studies identified. Studies originating in the US accrued 2753 patients, FIGU accrued more than double that of the US with 6527 patients and 4736 patients were accrued in the remaining countries. The mean number of patients randomized per trial for the 25 US studies was 110.2, compared to 205 for all non-USA trials (P ¼ 0.01) and compared to 222.6 for FIGU trials (P ¼ 0.006) ( Table 2) .
Overall, there was no significant trend in the mean number of patients accrued per study per year of publication for transplant studies. Multivariate analysis identified the focus of study, but not the year of publication or country of origin as predictive of the number of patients accrued per study. Significantly larger numbers of patients were accrued to studies of transplant versus conventional therapy (mean 279) compared to the other trial categories including conditioning regimen trials (mean 168), graft/ growth factor trials (mean 104), and GVHD trials (mean 124) (Po0.0001). No significant differences in accrual numbers were found among nontransplant studies.
Discussion
In 2002, 17 700 HSCTs were performed in the US, 10 14 989 in FIGU countries, and 24 154 for the entire Europe (including FIGU). 11 These data would suggest that US has one of the highest rates of HSCTs performed per capita, yet less than 2% of patients will participate in RCTs. Transplant studies in the US have focused on issues other than the comparison of transplant to conventional therapies. This trend may explain the low accrual numbers to US transplant RCTs, since this type of trial generally accrues larger numbers of patients.
Our data demonstrate a leading role for the US in RCTs aimed at improving the outcomes of HSCT, such as defining optimal conditioning regimens, the use of graft manipulation and growth factors, and GVHD prevention or treatment. Our data also underscore a serious deficit of US RCTs defining the role of HSCT versus conventional therapies in patients with hematological malignancies. While this type of trial may be the most relevant to clinical practice, current practice of HSCT as standard of care in the US is primarily based on data from European RCTs.
Transplant trials are nearly always published as full reports as long as they have completed the planned accrual. The lack of a full report would indicate a poor accrual or early closure of the trial due to unexpected outcomes. It is unlikely that our findings are due to publication bias. Eighty percent of the 83 transplant RCTs were published in three leading American journals (Blood, Journal of Clinical Oncology and New England Journal of Medicine).
It is evident from our data that US centers have great difficulties with RCTs when a transplant arm is compared to a nontransplant arm. Trials that compare two transplant arms appear not to encounter the same problem. The reasons for decreased productivity may be multifactorial.
Patients indicate that a potential personal benefit is the most important reason to participate in trials. 12, 13 Patients were also more likely to enter a trial when their physicians believed that the study was asking an important question. 12 Financial issues may also be an important factor. Clinical research in the US is currently supported largely by the pharmaceutical industry. 14, 15 Transplant RCTs are generally not conducive to new drug approval, and therefore are not likely to be supported by industry grants.
Health insurance coverage may be denied if patients receive therapy as part of a clinical trial. However, even in states where coverage for clinical trials is mandatory, accrual to RCT has remained poor. 16 When all factors are considered, the most important reason for poor accrual is the lack of an available RCT. 17 A recent review (January 2005) of NIH, NCI, ECOG, SWOG, and CALGB websites revealed only two currently active RCTs comparing HSCT to standard therapy for adult patients with hematological malignancies.
Measures have been initiated to improve clinical cancer research activities in this country. [18] [19] [20] New approaches need to be explored for the US to become more productive in HSCT RCTs, particularly related to those that compare transplant to conventional therapy. Important questions regarding the role of HSCT for patients with hematological malignancies remain unanswered.
The European experience shows that HSCT RCTs can be designed, completed, and reported in an efficient and timely manner.
